373 related articles for article (PubMed ID: 22012070)
1. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.
Furugohri T; Sugiyama N; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1076-83. PubMed ID: 22012070
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
Furugohri T; Morishima Y
Thromb Res; 2015 Sep; 136(3):658-62. PubMed ID: 26188924
[TBL] [Abstract][Full Text] [Related]
3. A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation.
Kamisato C; Furugohri T; Morishima Y
Thromb Res; 2016 May; 141():77-83. PubMed ID: 26974491
[TBL] [Abstract][Full Text] [Related]
4. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Perzborn E; Heitmeier S; Buetehorn U; Laux V
J Thromb Haemost; 2014 Jul; 12(7):1054-65. PubMed ID: 24766850
[TBL] [Abstract][Full Text] [Related]
5. Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats.
Furugohri T; Fukuda T; Tsuji N; Kita A; Morishima Y; Shibano T
Eur J Pharmacol; 2012 Jul; 686(1-3):74-80. PubMed ID: 22546231
[TBL] [Abstract][Full Text] [Related]
6. Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by paradoxical enhancement of thrombin generation: comparison with a direct factor Xa inhibitor edoxaban.
Morishima Y; Kamisato C; Honda Y
Blood Coagul Fibrinolysis; 2021 Apr; 32(3):209-215. PubMed ID: 33560005
[TBL] [Abstract][Full Text] [Related]
7. Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma.
Mohri M; Suzuki M; Sugimoto E; Sata M; Yamamoto S; Maruyama I
Thromb Haemost; 1998 Dec; 80(6):925-9. PubMed ID: 9869162
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Shirasaki Y; Morishima Y; Shibano T
Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
[TBL] [Abstract][Full Text] [Related]
9. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
[TBL] [Abstract][Full Text] [Related]
10. The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation.
Tanaka KA; Szlam F; Levy JH
Br J Haematol; 2006 Jul; 134(1):77-82. PubMed ID: 16803571
[TBL] [Abstract][Full Text] [Related]
11. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro.
Mattsson C; Menschik-Lundin A; Nylander S; Gyzander E; Deinum J
Thromb Res; 2001 Dec; 104(6):475-86. PubMed ID: 11755958
[TBL] [Abstract][Full Text] [Related]
12. Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.
Honda Y; Morishima Y
Thromb Res; 2015 May; 135(5):958-62. PubMed ID: 25791908
[TBL] [Abstract][Full Text] [Related]
13. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
[TBL] [Abstract][Full Text] [Related]
14. Covalent antithrombin-heparin effect on thrombin-thrombomodulin and activated protein C reaction with factor V/Va.
Van Walderveen MC; Berry LR; Atkinson HM; Chan AK
Thromb Haemost; 2010 May; 103(5):910-9. PubMed ID: 20216984
[TBL] [Abstract][Full Text] [Related]
15. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation--a comparison with other anticoagulants.
Mohri M; Sugimoto E; Sata M; Asano T
Thromb Haemost; 1999 Dec; 82(6):1687-93. PubMed ID: 10613656
[TBL] [Abstract][Full Text] [Related]
16. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Konishi N; Hiroe K; Kawamura M
Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor.
van 't Veer C; Golden NJ; Kalafatis M; Mann KG
J Biol Chem; 1997 Mar; 272(12):7983-94. PubMed ID: 9065469
[TBL] [Abstract][Full Text] [Related]
20. Evidence that the protein C activation pathway amplifies the inhibition of thrombin generation by recombinant human thrombomodulin in plasma.
Ohishi R; Watanabe N; Aritomi M; Gomi K; Kiyota T; Yamamoto S; Ishida T; Maruyama I
Thromb Haemost; 1993 Sep; 70(3):423-6. PubMed ID: 8259542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
